Emergence of Multidrug-resistant Salmonella Paratyphi B dT+, Canada

Michael R. Mulvey,* David Boyd,* Axel Cloeckaert,† Rafiq Ahmed,* Lai-King Ng,* and the Provincial Public Health Laboratories1

We document an increase in the number of multidrug-resistant Salmonella enterica serovar Paratyphi B dT+ identified in Canada. Most of these strains harbor Salmonella genomic island 1 (SGI1). Further studies are needed to determine factors contributing to the observed emergence of this multidrug-resistant strain.

Salmonella genomic island 1 (SGI1) was first characterized in Salmonella enterica serovar Typhimurium definitive phage type 104 (DT104). It consists of a 43-kb DNA segment harboring genes responsible for the pentaresistance phenotype ampicillin, chloramphenicol, streptomycin, sulphonamide, and tetracycline (ACSSuT) and is inserted into the chromosome at the end of the thdF gene (1). Complete nucleotide sequence of this region revealed 44 open reading frames, of which some displayed homology to genes associated with plasmid transfer, which suggests SGI1 may be at least partially plasmidic in origin (2). The SGI1 is associated with the multidrug-resistant DT104 clone that has disseminated worldwide (3). Recently, a clone that has disseminated worldwide (3). Recently, a

The Study

This report is a result of a collaborative effort between the National Microbiology Laboratory (NML), Health Canada, and the Provincial Public Health Laboratories (PPHLs) in Canada. The PPHLs represent every province in Canada and also include the Yukon and North West Territories. All S. Paratyphi B dT+ identified at the PPHLs were forwarded to the NML for additional characterization. Between 1998 and 2002, 252 S. Paratyphi B dT+ strains were submitted to the NML, of which 246 were from a human source. Distribution of the strains over time is shown in Figure 1. Incidence of S. Paratyphi B dT+ has generally increased since 1998; the spike in S. Paratyphi B dT+ in the third and fourth quarters of 1999 can be attributed to an outbreak in British Columbia, Alberta, and Saskatchewan caused by contaminated alfalfa sprouts (7). In addition to this large outbreak, additional outbreaks were reported between 1998 and 2002; however, each outbreak was small, and most involved fewer than six persons.

Antimicrobial susceptibility testing was performed on all strains by using the disk-diffusion method as described by the National Committee for Clinical Laboratory Standards (8).

Salmonella Paratyphi B dT+ isolates harboring SGI1 in Canada and also include the Yukon and North West Territories. All S. Paratyphi B dT+ identified at the PPHLs were forwarded to the NML for additional characterization. Between 1998 and 2002, 252 S. Paratyphi B dT+ strains were submitted to the NML, of which 246 were from a human source. Distribution of the strains over time is shown in Figure 1. Incidence of S. Paratyphi B dT+ has generally increased since 1998; the spike in S. Paratyphi B dT+ in the third and fourth quarters of 1999 can be attributed to an outbreak in British Columbia, Alberta, and Saskatchewan caused by contaminated alfalfa sprouts (7). In addition to this large outbreak, additional outbreaks were reported between 1998 and 2002; however, each outbreak was small, and most involved fewer than six persons.

Antimicrobial susceptibility testing was performed on all strains by using the disk-diffusion method as described by the National Committee for Clinical Laboratory Standards (8). Susceptibilities were determined for ampicillin (A), chloramphenicol (C), ciprofloxacin (Cp), streptomycin (S), sulphonmethoxazole (Su), tetracycline (T), and trimethoprim (Tm). Of the 237 strains examined for susceptibility, 123 (52%) were susceptible to all antimicrobial agents tested. Sixty-seven strains (28%) displayed the pentaresistance phenotype (ACSSuT), and the second most prevalent resistance profile was Su (n = 41, 17%). Single strains displayed the phenotypes A, T, CSSu, ASSu, and ACSuTTm. A significant increase was observed in ACSSuT strains over the time period from 1998 to 2002 (p < 0.001). Rates for the years are as follows: 1998, n = 2 (2%); 1999, n = 4 (18%); 2000, n = 2 (10.5%); 2001, n = 23 (39%); and 2002, n = 36 (58%). No large outbreaks were reported during this time period. To determine if the pentaresistance phenotype was caused by SGI1, polymerase chain reaction (PCR) was used to detect integrons and the left (thdF-S001) and right (S044-yidT) junctions of SGI1 as previously described (2). Of the 67 strains identified with the ACSSuT phenotype, 63 contained 1.0-kb and 1.2-kb integrons and left and right junctions of SGI1, which suggests that these strains contained SGI1 inserted into the same location on the chromosome as was described for DT104 (1). One strain with the ACSSuT phenotype contained 1.0-kb and 1.2-kb integrons and gave a PCR product for the left junction amplification reaction but not the right junction, which suggests that a portion of SGI1 downstream of the integrons was missing.

*Health Canada, Winnipeg, Manitoba, Canada; and †Institut National de la Recherche Agronomique, Nouzilly, France

1Provincial Public Health Laboratory Members: Lewis Abbott (Prince Edward Island), Kevin Forward (Nova Scotia), Glenna Hardy (New Brunswick), Greg Horsman (Saskatchewan), Judy Isaac-Rentont (British Columbia), Frances Jamieson (Ontario), Jean Joly (Quebec), Jutta K. Preiksaitis (Alberta), Sam Ratnam (Newfoundland), Paul Van Caeseele (Manitoba).
Three strains with the ACSSuT phenotype did not give the characteristic size products for integron (0.7 kb, n = 2; 2.0 kb, n = 1), and all were negative for the junction PCR, which suggests that these strains most likely harbored other resistance genes giving the ACSSuT phenotype. Only four strains with the ACSSuT phenotype were identified from a nonhuman source (one poultry, three environmental). Although the three environmental isolates contained SG11, the ACSSuT strain isolated from poultry did not; instead, it contained a 2-kb integron. Of the human isolates for which source was reported for the ACSSuT phenotype, 12 were isolated from stool, with the exception of three that were isolated from blood. To ensure that these strains did not cluster with the other ACSSuT strains did not harbor SG11 as described above.

Cluster 1 contained 32 strains that represented 10 subtypes. Cluster 2 contained 17 strains that represented 7 subtypes, all of which showed <7 band differences between strains from cluster 1. Cluster 3 contained 15 strains that represented 6 subtypes, all of which showed fewer than seven band differences between subtypes in cluster 2, but had more than seven band differences between the cluster 1 fingerprints. In addition, six other strains identified before 2000 were subtyped. Five were other ACSSuT identified in 1998 (n = 1) and 1999 (n = 4), and all were identified in cluster 2. In addition, one S. Paratyphi B dT* recently shown to harbor SG11 that was isolated in Singapore from a fish was grouped into cluster 3 (4). The Canadian isolates in clusters 1 to 3 have been identified from multiple provinces, including British Columbia, Alberta, Manitoba, Ontario, and Québec, representing western and central regions of Canada.

**Conclusions**

The emergence of multidrug-resistant S. Paratyphi B dT* was documented recently in the Netherlands and Scotland (11,12). Some isolates had the ACSSuT susceptibility pattern and did not harbor any plasmids, which suggests the resistance is of chromosomal origin (12).
However, in neither study was the presence of SGI1 or other resistance genes examined. We demonstrate the rapid emergence of multidrug-resistant *S.* Paratyphi B dT+ in Canada. The increase is due to three clusters, all of which contain the multidrug-resistant genomic island SGI1. That three closely related clonal groups were present suggests SGI1 may have inserted into the genome of *S.* Paratyphi B dT+ in three separate events, as shown by clusters 1, 2, and 3, or the insertion may have occurred once, with strains diverging over time. We also identified three strains with the ACSSuT phenotype that did not contain SGI1 sequences, which emphasizes the need to monitor genotypic resistance factors and not just phenotypic resistance traits to understand the dissemination of antimicrobial resistance.

The emergence of multidrug-resistant enteric pathogens is a concern because of the lack of suitable antimicrobial agents available to treat invasive infections. One organism that emerged in the 1990s is multidrug-resistant *S.* Typhimurium DT104, which harbors SGI1 (3). Along with the multidrug-resistant phenotype, reports suggest the strain may be more virulent than other salmonellae (13,14). However, in vitro studies have not shown any increase in invasiveness or survival in mammalian cells (15,16). Whether multidrug-resistant DT104 is more virulent remains to be determined, the underlying question remains: why has this clone of DT104 emerged as a major pathogen? Selective pressure, resulting from the widespread use of antimicrobial drugs in animals for growth promotion or prophylaxis, may have played a role in disseminating this organism. However, this factor may not completely account for its prevalence, because other multidrug-resistant strains of DT104 have emerged but have not disseminated internationally. Other factors may contribute to the international dissemination of this clone. For example, additional determinants in SGI1 may contribute to the fitness or virulence of *Salmonella* strains harboring it. In the present study, three closely related clusters of *S.* Paratyphi B dT+ carrying SGI1 have emerged in Canada and make up 46% (64 of 139) of all strains identified in 2001 and 2002. Furthermore, three additional *S.* Paratyphi B dT+ strains with the ACSSuT phenotype were identified that do not harbor SGI1 and do not appear to be rapidly increasing in Canada. In this hypothesis, SGI1 may predict the next emerging *Salmonella* serotype. Other factors, such as processing food products and the structure of the food distribution system, could play a role in disseminating these organisms. We continue to monitor this pathogen and are designing studies to improve understanding of the epidemiology of *S.* Paratyphi B dT+ in Canada. We suggest all strains of *Salmonella* with the ACSSuT phenotype be examined for SGI1.

**Acknowledgments**

We thank Dave Spreitzer for PFGE analysis, Kevin Nelson for PCR analysis, and Derrick Ozunko for antimicrobial susceptibility testing.

This work was funded by Health Canada and the Provincial Public Health Laboratories.

Dr. Mulvey is chief of Antimicrobial Resistance and Nosocomial Infections at the National Microbiology Laboratory, Health Canada. His main interests are antimicrobial resistance mechanisms and the dissemination of resistance genes.

**References**

Instructions for Emerging Infectious Diseases Authors

**Research Studies:** Articles should be 2,000 to 3,500 words and should include references, not to exceed 40. Use of subheadings in the main body of the text is recommended. Photographs and illustrations are encouraged. Provide a short abstract (150 words) and a brief biographical sketch of first author—both authors if only two.

These articles report laboratory and epidemiologic results within a public health perspective. Although these reports may be written in the style of traditional research articles, they should explain the value of the research in public health terms and place the findings in a larger perspective (e.g., “Here is what we found, and here is what the findings mean”).

**Manuscript Preparation.** For word processing, use MS Word. Begin each of the following sections on a new page and in this order: title page, keywords, abstract, text, acknowledgments, biographical sketch, references, tables, figure legends, appendixes, and figures. Each figure should be in a separate file.

**Title Page.** Give complete information about each author (i.e., full name, graduate degree(s), affiliation, and the name of the institution in which the work was done). Clearly identify the corresponding author and provide that author’s mailing address (include phone number, fax number, and e-mail address). Include separate word counts for abstract and text.

**Keywords.** Include up to 10 keywords; use terms listed in Medical Subject Headings Index Medicus.

**Text.** Double-space everything, including the title page, abstract, references, tables, and figure legends. Printed manuscript should be single-sided, beginning with the title page. Indent paragraphs; leave no extra space between paragraphs. After a period, leave only one space before beginning the next sentence. Use 12-point Times New Roman font and format with ragged right margins (left align). Italicize (rather than underline) scientific names when needed.

**Biographical Sketch.** Include a short biographical sketch of the first author—both authors if only two. Include affiliations and the author’s primary research interests.

**References.** Follow Uniform Requirements (www.icmje.org/index.html). Do not use endnotes for references. Place reference numbers in parentheses, not superscripts. Number citations in order of appearance (including in text, figures, and tables). Cite personal communications, unpublished data, and manuscripts in preparation or submitted for publication in parentheses in text. Consult List of Journals Indexed in Index Medicus for accepted journal abbreviations; if a journal is not listed, spell out the journal title. List the first six authors followed by “et al.” Do not cite references in the abstract.

**Tables and Figures.** Create tables within MS Word’s table tool. Do not format tables as columns or tabs. Send graphics in native, high-resolution (400-dpi minimum) .TIFF (Tagged Image File), or .EPS (Encapsulated Postscript) format. Graphics should be in a separate electronic file from the text file. For graphic files, use Arial font. Convert Macintosh files into the suggested PC format. Figures, symbols, letters, and numbers should be large enough to remain legible when reduced. Place figure keys within the figure. For more information see EID Style Guide (http://www.cdc.gov/ncidod/EID/style_guide.htm).

**Manuscript Submission.** Include a cover letter indicating the proposed category of the article (e.g., Research, Dispatch) and verifying that the final manuscript has been seen and approved by all authors. Submit an electronic copy (by e-mail) to the Editor, eeditor@cdc.gov.